Xellia Pharms Aps Company Profile
✉ Email this page to a colleague
What is the competitive landscape for XELLIA PHARMS APS, and when can generic versions of XELLIA PHARMS APS drugs launch?
XELLIA PHARMS APS has sixteen approved drugs.
There are seven US patents protecting XELLIA PHARMS APS drugs.
There are fifty patent family members on XELLIA PHARMS APS drugs in thirty countries and twenty-eight supplementary protection certificates in nine countries.
Summary for Xellia Pharms Aps
| International Patents: | 50 |
| US Patents: | 7 |
| Tradenames: | 10 |
| Ingredients: | 10 |
| NDAs: | 16 |
Drugs and US Patents for Xellia Pharms Aps
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xellia Pharms Aps | VANCOMYCIN HYDROCHLORIDE | vancomycin hydrochloride | SOLUTION;INTRAVENOUS | 211962-006 | May 13, 2020 | RX | Yes | Yes | 10,849,956 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Xellia Pharms Aps | VANCOMYCIN HYDROCHLORIDE | vancomycin hydrochloride | SOLUTION;INTRAVENOUS | 211962-003 | Feb 15, 2019 | RX | Yes | Yes | 11,628,200 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Xellia Pharms Aps | VANCOMYCIN HYDROCHLORIDE | vancomycin hydrochloride | SOLUTION;INTRAVENOUS | 211962-007 | May 13, 2020 | RX | Yes | Yes | 11,628,200 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Xellia Pharms Aps | VANCOMYCIN HYDROCHLORIDE | vancomycin hydrochloride | INJECTABLE;INJECTION | 204107-001 | Dec 28, 2015 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Xellia Pharms Aps | MICAFUNGIN SODIUM | micafungin sodium | INJECTABLE;INTRAVENOUS | 211713-001 | Jun 2, 2021 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Xellia Pharms Aps Drugs
Supplementary Protection Certificates for Xellia Pharms Aps Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0440372 | 02C0030 | France | ⤷ Sign Up | PRODUCT NAME: VORICONAZOLE; NAT. REGISTRATION NO/DATE: EU/1/02/212/001-025 20020319; FIRST REGISTRATION: EU/1/02/212/001-25 20020319 |
| 1115417 | CA 2006 00018 | Denmark | ⤷ Sign Up | PRODUCT NAME: DAPTOMYCIN |
| 0536515 | 06C0031 | France | ⤷ Sign Up | PRODUCT NAME: TIGECYCLINE; REGISTRATION NO/DATE: EU/01/06/336/001 20060424 |
| 1280520 | C300722 | Netherlands | ⤷ Sign Up | PRODUCT NAME: TOBRAMYCINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: C(2011)5394 20110720 |
| 0788511 | C00788511/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: MICAFUNGIN; REGISTRATION NO/DATE: SWISSMEDIC 60724 11.07.2012 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
